Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris(Bayer (United States)), Stefan D. Anker(Bayer (Germany)), Luís M. Ruilope(Bayer (Germany)), Bertram Pitt(Bayer (Germany)), Patrick Schloemer(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Christina Nowack(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Peter Rossing(Steno Diabetes Centers), Rajiv Agarwal(Richard L. Roudebush VA Medical Center), Amer Joseph(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Peter Kolkhof(Berlin Institute of Health at Charité - Universitätsmedizin Berlin)
Cited by 2,632
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k